
Mixed outcomes with novel targeted therapies for HER2-positive upper GI cancers
While a HER2-targeted bispecific antibody showed extended survival in pre-treated gastric cancers, TKI–immunotherapy combinations failed to confer a survival benefit
While a HER2-targeted bispecific antibody showed extended survival in pre-treated gastric cancers, TKI–immunotherapy combinations failed to confer a survival benefit
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
Quality of life and pain management data adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy
Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
The availability of simpler, less-invasive methodologies may help to encourage participation in secondary prevention programmes
Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment
Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE
Newer technologies build on current knowledge to provide greater insights in the molecular landscape
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.